Open-label, Phase 1 Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors

Trial Profile

Open-label, Phase 1 Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Natural killer cell therapy (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms QUILT-3.028
  • Sponsors NantKwest
  • Most Recent Events

    • 25 Jan 2017 New trial record
    • 23 Jan 2017 According to NantKwest media release, U.S. Food and Drug Administration (FDA) has authorized the companys Investigational New Drug Application (IND) of this phase I study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top